Evidence map›Paper›PMID 27130348›Full record

Observational studyJournal of the American Heart Association2016

Remnant Lipoprotein Cholesterol and Incident Coronary Heart Disease: The Jackson Heart and Framingham Offspring Cohort Studies.

Parag H Joshi, Arif A Khokhar, Joseph M Massaro, Seth T Lirette, Michael E Griswold, Seth S Martin, Michael J Blaha, Krishnaji R Kulkarni, Adolfo Correa, Ralph B D'Agostino and 3 more

Registry-linked trialOpen access · goldAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Journal of the American Heart Association, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00415415 (Disparities in CHD in the Jackson Heart Study), which is not on this map. Cited by 83 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
83citing papers in PubMed, 1 pooled it
10.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00415415 completednot on this map

Disparities in CHD in the Jackson Heart Study

TypeobservationalSponsorNational Heart, Lung, and Blood Institute (NHLBI)Ran2000 to 2004Enrolled5,302ConditionsCardiovascular Diseases, Coronary Disease
3 · Its place in the literature

Who cites it

83 citing papers in PubMed, 1 synthesis or guideline pooled it, 173 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Targeting triglycerides for cardiovascular risk reduction.Internal and emergency medicine · 2026
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Inflammation and the Heart: The Role of Traditional Factors.Cardiology research and practice · 2026
    Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. New approaches to triglyceride reduction: Is there any hope left?American journal of preventive cardiology · 2024
    Article
  20. Article

23 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 2 countries.

Parag H JoshiJohns Hopkins Ciccarone Center for the Prevention of Heart Disease, Baltimore, MD Division of Cardiology, University of Texas Southwestern Medical Center, Dallas, TX parag.joshi@utsouthwestern.edu.
Arif A KhokharRoyal Brompton and Harefield NHS Trust, London, UK.
Joseph M MassaroDepartment of Biostatistics, Boston University School of Public Health, Boston, MA.
Seth T LiretteCenter of Biostatistics & Bioinformatics, University of Mississippi Medical Center, Jackson, MS Jackson Heart Study, University of Mississippi Medical Center, Jackson, MS.
Michael E GriswoldCenter of Biostatistics & Bioinformatics, University of Mississippi Medical Center, Jackson, MS Jackson Heart Study, University of Mississippi Medical Center, Jackson, MS.
Seth S MartinJohns Hopkins Ciccarone Center for the Prevention of Heart Disease, Baltimore, MD.
Michael J BlahaJohns Hopkins Ciccarone Center for the Prevention of Heart Disease, Baltimore, MD.
Krishnaji R KulkarniAtherotech Diagnostics Laboratory, Birmingham, AL.
Adolfo CorreaJackson Heart Study, University of Mississippi Medical Center, Jackson, MS.
Ralph B D'AgostinoDepartment of Biostatistics, Boston University School of Public Health, Boston, MA.
Steven R JonesJohns Hopkins Ciccarone Center for the Prevention of Heart Disease, Baltimore, MD.
Peter P TothJohns Hopkins Ciccarone Center for the Prevention of Heart Disease, Baltimore, MD CGH Medical Center, Sterling, IL University of Illinois School of Medicine, Peoria, IL.
Lipoprotein Investigators Collaborative (LIC) Study Group
Jackson Memorial Hospital · USBoston University · USAC Diagnostics (United States) · USJohns Hopkins University · USRoyal Brompton & Harefield NHS Foundation Trust · GBThe University of Texas Southwestern Medical Center · US

Funding

PATHOPHYSIOLOGY OF MYOCARDIAL DISEASEST32HL007227 · JOHNS HOPKINS UNIVERSITY · 1985 to 2025
$4.3M
CARDIOVASCULAR EPIDEMIOLOGY INSTITUTIONAL TRAININGT32HL007024 · JOHNS HOPKINS UNIVERSITY · 1985 to 2025
$3.7M
NHLBI NIH HHS HHSN268201300046CNHLBI NIH HHS HHSN268201300047CNHLBI NIH HHS HHSN268201300048CNHLBI NIH HHS HHSN268201300049CNHLBI NIH HHS HHSN268201300050CNHLBI NIH HHS T32 HL007024NHLBI NIH HHS T32 HL007227
6 · The paper itself

Abstract

backgroundRemnant lipoproteins (RLPs), the triglyceride-enriched precursors to low-density lipoprotein, are an emerging risk factor for coronary heart disease (CHD). We sought to determine the association of RLP cholesterol (RLP-C) levels with incident CHD in 2 diverse, prospective, longitudinal observational US cohorts. METHODS AND

resultsWe analyzed cholesterol levels from serum lipoprotein samples separated via density gradient ultracentrifugation in 4114 US black participants (mean age 53.8 years, 64% women) from the Jackson Heart Study and a random sample of 818 predominantly white participants (mean age 57.3 years, 52% women) from the Framingham Offspring Cohort Study. Multivariable-adjusted hazard ratios (HRs) for RLP-C (the sum of very low-density lipoprotein3 cholesterol and intermediate-density lipoprotein cholesterol) were derived to estimate associations with incident CHD events consisting of myocardial infarction, CHD death, and revascularizations for each cohort separately and as a combined population. There were 146 CHD events in the combined population. After adjustments for age, sex, body mass index, smoking, blood pressure, diabetes, and lipid-lowering therapy for the combined population, RLP-C (HR 1.23 per 1-SD increase, 95% CI 1.06-1.42, P<0.01) and intermediate-density lipoprotein cholesterol (HR 1.26 per 1-SD increase, 95% CI 1.08-1.47, P<0.01) predicted CHD during an 8-year follow-up. Associations were attenuated by high-density lipoprotein cholesterol and ultimately lost significance with inclusion of real low-density lipoprotein cholesterol, which excludes Lp(a) and IDL cholesterol fractions. Similar associations were seen in multivariable analyses within each cohort.

conclusionRLP-C levels are predictive of incident CHD in this diverse group of primary prevention subjects. Interventions aimed at reducing RLP-C to prevent CHD warrant further intensive investigation. CLINICAL

trial registrationURL: http://www.ClinicalTrials.gov. Unique identifier: NCT00415415.

Indexed as

AdultAgedCholesterolCholesterol, HDLCholesterol, VLDLCohort StudiesCoronary DiseaseFemaleHumansIncidenceLipoprotein(a)LipoproteinsLongitudinal StudiesMaleMiddle AgedMultivariate AnalysisCholesterolCholesterol, HDLCholesterol, VLDLLipoprotein(a)lipoprotein cholesterolLipoproteinsremnant-like particle cholesterolTriglyceridescoronary heart diseaselipidsprimary preventionremnant lipoprotein cholesteroltriglycerides

Identifiers

PMID27130348
PMCPMC4889167
OpenAlexW2342925409

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.